New scan could help predict chemotherapy success in breast cancer
NCT ID NCT04332588
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a special PET/MRI scan using an investigational tracer called [18F]FMISO can help monitor how well chemotherapy works in people with HER2-positive breast cancer. The study involves 25 patients and is for imaging purposes only—it will not change their current treatment plan. The goal is to help doctors better understand and predict treatment response in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- [18F]FMISO (a radioactive tracer used for PET imaging)
- What this could lead to
- If successful, this could give doctors a better way to see early on whether chemotherapy is working for HER2+ breast cancer, potentially guiding more personalized treatment in the future.
- What could go wrong
- This is a very small, early-phase imaging study (25 participants) and is not designed to test a treatment. The results may not lead to changes in how patients are treated right now.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35249, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?